We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

169 hedge funds and large institutions have $790M invested in Ariad Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

19% more call options, than puts

Call options by funds: $31.5M | Put options by funds: $26.5M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

7% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 29

1% less funds holding

Funds holding: 171 → 169 (-2)

10% less capital invested

Capital invested by funds: $877M → $790M (-$86.6M)

Holders
169
Holders Change
-2
Holders Change %
-1.17%
% of All Funds
4.86%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
27
Increased
63
Reduced
44
Closed
29
Calls
$31.5M
Puts
$26.5M
Net Calls
+$5.02M
Net Calls Change
+$1.41M

Top Buyers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
+$20.4M
2
BFA
BlackRock Fund Advisors
California
+$19.5M
3
Renaissance Technologies
Renaissance Technologies
New York
+$14.8M
4
Norges Bank
Norges Bank
Norway
+$14.6M
5
CCM
Camber Capital Management
Massachusetts
+$13.8M

Top Sellers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
-$53.4M
2
PAI
Palo Alto Investors
California
-$8.14M
3
ARTA
A.R.T. Advisors
New York
-$4.58M
4
Citadel Advisors
Citadel Advisors
Florida
-$3.23M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
OIA
151
Optimum Investment Advisors
Illinois
$10K +$344 +50 +3%
PO
152
Private Ocean
California
$6K -$6.88K -1,000 -50%
MCM
153
Manchester Capital Management
Vermont
$6K – – –
OSNBOA
154
Old Second National Bank of Aurora
Illinois
$6K – – –
BJ
155
BlackRock Japan
Japan
$6K +$6.06K +881 New
BRWA
156
B. Riley Wealth Advisors
Florida
$4.46K +$4.81K +700 New
TCOV
157
Trust Company of Vermont
Vermont
$4K – – –
ST
158
Stifel Trust
Missouri
$3K -$55K -8,000 -95%
BRWM
159
B. Riley Wealth Management
Tennessee
$3K – – –
KT
160
Kanaly Trust
Texas
$3K – – –
TDC
161
Thompson Davis & Co
Virginia
$3K – – –
MFS
162
MSI Financial Services
Massachusetts
$2K -$2.06K -300 -46%
DADC
163
D.A. Davidson & Co
Montana
$2K – – –
SNT
164
Security National Trust
West Virginia
$2K – – –
LWA
165
Lenox Wealth Advisors
New York
$1K – – –
PIM
166
Parasol Investment Management
Illinois
$1K – – –
Walleye Trading
167
Walleye Trading
New York
$82 +$51.6K +7,500 +140%
SPC
168
Slate Path Capital
New York
– -$53.4M -6,620,000 Closed
ARTA
169
A.R.T. Advisors
New York
– -$4.58M -568,559 Closed
Allianz Asset Management
170
Allianz Asset Management
Germany
– -$2.81M -349,200 Closed
ZIM
171
Zacks Investment Management
Illinois
– -$2.14M -265,676 Closed
BB
172
BB Biotech
Switzerland
– -$1.38M -171,517 Closed
LCM
173
LG Capital Management
Maryland
– -$1.27M -158,100 Closed
State of Wisconsin Investment Board
174
State of Wisconsin Investment Board
Wisconsin
– -$1.06M -132,020 Closed
TAM
175
Tocqueville Asset Management
New York
– -$463K -57,500 Closed
4 5 6
7
8

ARIA Hedge Fund Activity: Q2 2014 in Review

169 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2014, worth a combined $790M — down 9.9% from $877M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ARIA and 27 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 63 added.

The largest buyer was AQR Capital Management, adding an estimated $20.4M. The largest seller was Slate Path Capital, exiting entirely with an estimated $53.4M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2014, down from 171 in Q1 2014.
  • Funds reported $790M of Ariad Pharmaceuticals Inc stock for Q2 2014, down 9.9% quarter-over-quarter.
  • 27 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2014 and 29 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q2 2014 was AQR Capital Management, an estimated $20.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q2 2014 was Slate Path Capital, an estimated $53.4M sold.

Based on aggregated 13F filings for Q2 2014.